Rarity Bioscience Announces That ARUP Laboratories Has Become the First U.S. Reference Lab To Validate Its Ultra-Sensitive superRCA Assay
UPPSALA, SWEDEN, and SALT LAKE CITY (February 3, 2026) – Sweden-based Rarity Bioscience today announced that ARUP Laboratories, a leading national reference laboratory and nonprofit enterprise of the University of Utah, has become the first commercial laboratory in the United States to validate and offer its groundbreaking superRCA™ assay for research applications. Ultra-Sensitive superRCA™ Technology […]
Rarity Bioscience Expands into the United States
With a growing customer base in North America, Rarity Bioscience has now established a subsidiary, Rarity Bioscience Inc., incorporated in Delaware, USA — a key step in strengthening our international operations and supporting our North American customers and partners. This marks an important milestone in Rarity Bioscience’s international expansion and will serve as a strategic […]
Rarity Bioscience wins prestigious Disruptive Technology Award
Rarity Bioscience has received the prestigious Disruptive Technology Award for its proprietary technology, superRCA™, which enables exceptionally sensitive detection of DNA mutations in common samples. The technology can detect a single mutation among 100,000 normal molecules – a capability that is critical for patients with cancer and other mutation-driven diseases, where early diagnosis, treatment monitoring, […]
Andrea Ballagi joins Rarity Bioscience
We are delighted to welcome Dr. Andrea Ballagi to the board of Rarity Bioscience. Dr. Ballagi brings extensive expertise in commercializing innovative biotechnological solutions. Her background uniquely combines both clinical and research perspectives — as a physician and a cancer researcher with a PhD. Experience from Olink, Thermo Scientific, and IDEXX Laboratories Over the years, […]
Rarity Bioscience Partners with Beckman Coulter Life Sciences
We are proud to announce that Rarity Bioscience is partnering with Beckman Coulter Life Sciences – a collaboration that will elevate oncology research by making the superRCA technology accessible to a global audience. Expanding Flow Cytometry’s Capabilities Partnering with Beckman Coulter Life Sciences enables the global distribution of Rarity Bioscience’s ultra-sensitive superRCA assays, ensuring broader […]
Rarity Bioscience Launches Cutting-Edge superRCA Mutation Detection Kit
Rarity Bioscience is thrilled to announce the release of its pioneering superRCA NPM1 Mutation Kit RUO™ and its universal Accessory Kit, designed to bring advanced mutation detection capabilities directly into your flow cytometry workflow. This innovative kit facilitates highly sensitive DNA based molecular analysis, delivering precise and quantitative Mutant Allele Frequency (MAF) in blood and […]
Nicolas Roelofs joins Rarity Bioscience
Nick brings over 40 years of leadership in the life sciences tools and diagnostics industry, having shaped the strategic direction of companies like Agilent Technologies and Bio-Rad Laboratories. With deep expertise in chemistry, he served as President of Agilent’s Life Sciences Group, leading a $4 billion global business, including acquisitions such as Halo Genomics. At […]
Rarity Bioscience – Gold Sponsor at ESCCA 2024
We are excited to announce that Rarity Bioscience is a Gold Sponsor at the upcoming ESCCA 2024 Conference, reaffirming our commitment to advancing scientific cell analysis. The European Society for Clinical Cell Analysis (ESCCA) Conference is a leading event that unites top experts and researchers worldwide to discuss cutting-edge developments in flow cytometry and related technologies.
Joseph Bernardo joins Rarity Bioscience
Mr. Joe Bernardo joins Rarity Bioscience as a private investor in a recent funding round. Additionally, he will take on the role of Strategic Business Advisor to the board, with a primary focus on commercialization, partnerships, and expanding into the US market.
Rarity Bioscience Closes €6.5M Funding Round Led By Navigare Ventures
Rarity Bioscience is pleased to announce the successful closure of a €6.5 million funding round. This latest round of investment was led by Navigare Ventures, with strong support from existing shareholders, including Novalis Biotech and UU Invest, as well as external strategic investors.